During a live event, Daniel M. Geynisman, MD, and participants discussed their answers to a poll on which combination to use ...

In the trial, researchers are evaluating Scancell's DNA cancer vaccines SCIB1 and iSCIB1+ alongside immunotherapy.

A biotech company based out of Ireland saw its shares soar on Tuesday after the company announced that it is discontinuing ...

Updated phase 3 data support pembrolizumab plus concurrent chemoradiotherapy as a standard of care for patients with high-risk, locally advanced cervical cancer, according to Linda Duska, MD.

Enriqueta Felip, MD, PhD, discusses the design of the phase 3 3475A-D77 trial evaluating subcutaneous pembrolizumab in ...

Oncology Clinical Trials Market has been steadily growing over the years due to increasing incidence of cancer, advancements ...

Delcath Systems, Inc., an interventional oncology company focused on the treatment of primary and metastatic liver cancers, annou ...

Summit Therapeutics' ivonescimab shows potential in cancer treatment, but high risks and valuation concerns suggest caution.

Immunotherapy is key for triple-negative breast cancer, but a new study finds Black women are receiving it less often than White women.

CEOs exercise warrants early, signaling bullish confidence ahead of a key Phase 3 trial data release. Read more here.

An April 6 article in the WaPo, one of the most recent as the NIH undergoes administrative changes, claims, “A big step forward in cancer therapy has been slowed by layoffs and ...

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update 10.04.2025 / 13:12 CET/CEST The issuer is solely responsible for the content of this ...